Dr. Reddy's demonstrated strong revenue growth and strategic advancements in its biosimilar business. However, challenges in the U.S. generics market due to price erosion and regulatory observations at manufacturing facilities present notable concerns.

Company Guidance

During the Q1 FY '26 earnings call for Dr. Reddy's Laboratories, the company reported notable financial and strategic performance metrics. Revenues for the quarter reached INR 8,545 crores (USD 997 million), marking an 11% year-over-year growth, driven by steady performance across most markets except the U.S. generics segment. The EBITDA margin was reported at 26.7%, slightly surpassing the company's 25% target. Gross profit margin stood at 56.9%, with a sequential improvement of 134 basis points. SG&A expenses increased by 13% year-over-year, primarily due to strategic investments in the consumer healthcare business, representing 30% of total sales. R&D spending was INR 624 crores (USD 73 million), mainly invested in complex generics, API, and biosimilars, equating to 7.3% of sales. The company highlighted its strategic focus on semaglutide and abatacept in its pipeline, alongside expanding its consumer health and biosimilars presence. Dr. Reddy's closed the quarter with a net cash surplus of USD 341 million and emphasized ongoing efforts to optimize structural costs and drive operational efficiencies.

Double-Digit Revenue Growth

Dr. Reddy's delivered a steady double-digit revenue growth of 11% year-over-year, driven by the consumer health care business and steady performance across most markets.

Biosimilar Business Momentum

The biosimilar business gained momentum through a strategic collaboration with Alvotech for pembrolizumab, a biosimilar to Keytruda.

Strong Balance Sheet

The company closed the quarter with a net cash surplus of $341 million, reinforcing a strong balance sheet position.

Sustainability Recognition

Dr. Reddy's received an elevated CDP rating to an A in the climate category, making it the only Indian pharmaceutical company with this score and among the top 2% globally.

Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IN:DRREDDY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2026 (Q2)	17.59 / -	15.04	―	―	―
Jul 23, 2025	2026 (Q1)	18.38 / 17.02	16.692	1.97% (+0.33)	―	―
May 09, 2025	2025 (Q4)	18.18 / 19.11	15.67	21.95% (+3.44)	―	―
Jan 23, 2025	2025 (Q3)	17.91 / 16.94	16.536	2.44% (+0.40)	―	―
Nov 05, 2024	2025 (Q2)	17.33 / 15.04	17.756	-15.30% (-2.72)	―	―
Jul 27, 2024	2025 (Q1)	16.06 / 16.69	16.844	-0.90% (-0.15)	―	―
May 07, 2024	2024 (Q4)	14.70 / 15.67	11.524	35.98% (+4.15)	―	―
Jan 30, 2024	2024 (Q3)	14.68 / 16.54	14.99	10.31% (+1.55)	―	―
Oct 27, 2023	2024 (Q2)	14.49 / 17.76	13.378	32.73% (+4.38)	―	―
Jul 26, 2023	2024 (Q1)	12.68 / 16.84	14.28	17.96% (+2.56)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IN:DRREDDY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 23, 2025	₹1240.40	₹1247.55	+0.58%
May 09, 2025	₹1141.46	₹1149.11	+0.67%
Jan 23, 2025	₹1288.13	₹1281.22	-0.54%
Nov 05, 2024	₹1259.96	₹1264.53	+0.36%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) report earnings?

Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) is schdueled to report earning on Oct 24, 2025, Before Open (Confirmed).

What is Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) earnings time?

Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) earnings time is at Oct 24, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Dr. Reddy's Laboratories Ltd. stock?

The P/E ratio of Dr. Reddy's Laboratories Ltd. is N/A.

What is IN:DRREDDY EPS forecast?

IN:DRREDDY EPS forecast for the fiscal quarter 2026 (Q2) is 17.59.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing